Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

Globe Newswire - Tue May 10, 2022

First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression

Total revenues for the first quarter 2022 were $35 million, compared to $15.9 million for the same period in 2021, representing a 120% increase

Read more at globenewswire.com